Salbutamol wzf 4 mg (DrugBank: Salbutamol)
14 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
3 | 脊髄性筋萎縮症 | 0 |
11 | 重症筋無力症 | 1 |
12 | 先天性筋無力症候群 | 0 |
13 | 多発性硬化症/視神経脊髄炎 | 0 |
49 | 全身性エリテマトーデス | 0 |
85 | 特発性間質性肺炎 | 0 |
86 | 肺動脈性肺高血圧症 | 0 |
89 | リンパ脈管筋腫症 | 0 |
111 | 先天性ミオパチー | 0 |
113 | 筋ジストロフィー | 0 |
228 | 閉塞性細気管支炎 | 0 |
231 | α1-アンチトリプシン欠乏症 | 0 |
256 | 筋型糖原病 | 0 |
299 | 嚢胞性線維症 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2019-000895-40-DK (EUCTR) | 28/03/2019 | 26/02/2019 | Beta-agonist Efficacy and Tolerability as Adjuvant therapy in Myasthenia Gravis | Beta-agonist Efficacy and Tolerability as Adjuvant therapy in Myasthenia Gravis - BETA-MG | Myasthenia Gravis MedDRA version: 21.1;Level: PT;Classification code 10028417;Term: Myasthenia gravis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Trade Name: Salbutamol WZF 4 mg INN or Proposed INN: Salbutamol Other descriptive name: SALBUTAMOL SULFATE PH. EUR. | Aarhus University Hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Phase 3 | Denmark |